Firefly Bio is a biotechnology company focused on developing new classes of payloads for Antibody-Drug Conjugates (ADCs) with the help of renowned researchers with decades of experience in ADC discovery and development.

Firefly Bio

Realizing the full potential of ADCs by unlocking new classes of payloads

Firefly is excited to share that we've closed a $94M Series A to advance Degrader Antibody Conjugates (DACs) that combine the unique strengths of ADCs with selective protein degraders. We're funded by Versant Ventures, MPM BioImpact, Decheng Capital, and Eli Lilly & Co. 
https://lnkd.in/grEAF9U8

COM:FIREFLYBIOLOGICS

Firefly Bio